Termination of early pregnancy by a single-dose 3.0 mg 15-methyl PGF2alpha methyl ester vaginal suppository.
The abortifacient effect of a single-dose, long-acting vaginal suppository containing 3.0 mg of 15-methyl PGF2 alpha methyl ester was investigated in 104 early pregnancies. The pregnancy was terminated in 91 per cent of the cases. The abortion was uncomplicated in 79 patients, while 12 patients experienced prolonged bleeding. In 21 uncomplicated cases, VabraR curettage done 4 weeks after therapy revealed necrotic residual tissue in 16 patients and nonspecific endometritis in 20 patients. Residual tissue was found in about 50 per cent of the patients curettaged after 1st menstruation, but no residua was found after 2nd menstruation. In patients with prolonged bleeding, substantial amounts of necrotic residual tissue was found in all patients curettaged 4 weeks after therapy. The decline of serum hCg and plasma progesterone levels was significantly slower in these patients as compared with uneventful abortions.
D000019:Abortifacient Agents; D000020:Abortifacient Agents, Nonsteroidal; D000293:Adolescent; D000328:Adult; D006063:Chorionic Gonadotropin / Q000097:blood; D004717:Endometrium / Q000473:pathology; D005260:Female; D006801:Humans; D009336:Necrosis; D010060:Ovulation; D010146:Pain / Q000139:chemically induced; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D011459:Prostaglandins E, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D013488:Suppositories; D013997:Time Factors; D014621:Vagina
D000019:Abortifacient Agents; D000020:Abortifacient Agents, Nonsteroidal; D006063:Chorionic Gonadotropin; D011459:Prostaglandins E, Synthetic; D013488:Suppositories; D011374:Progesterone